In light of the recent terror attack, India is reviewing its pharmaceutical exports to Pakistan. The Department of ...

Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India.

Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

India may have a dengue vaccine as early as next year. Developed by Japanese major Takeda, the vaccine named ‘Qdenga’ will be ...

This article is authored by Deepak Kapur, chairman, Rotary International India’s National PolioPlus Committee (RI-INPPC).

The company plans to introduce Beyfortus, which contains the monoclonal antibody, nirsevimab, in a prefilled injection used ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody nirsevimab, in a prefilled injection used ...

Dr Sita Rama Budaraja, Advisor, Health, Tata Trusts, underscores that addressing healthcare gaps in marginalized communities, ...

The Pandemic Agreement is a legally-binding deal in which countries agree to an international response to pandemic. It ...

Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration ...